Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Peripheral × Salvage Therapy × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Recurrence 1 Rectal Neoplasms 1 Neuroendocrine Tumors 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Leukemia, Myeloid, Acute 1 Leukemia, Erythroblastic, Acute 1 Hodgkin Disease 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 38 Prednisone 29 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 26 Vincristine 24 Doxorubicin 24 romidepsin 19 Etoposide 19 Gemcitabine 17 10-propargyl-10-deazaaminopterin 15 fludarabine phosphate 14 Whole-Body Irradiation 13 Lenalidomide 13 Azacitidine 13 Peripheral Blood Stem Cell Transplantation 12 Mycophenolic Acid 11 Brentuximab Vedotin 11 Dexamethasone 10 Bortezomib 10 Cyclosporine 9 Alemtuzumab 8 fludarabine 7 Rituximab 7 belinostat 6 Cytarabine 6 Methotrexate 5 Granulocyte Colony-Stimulating Factor 5 Bendamustine Hydrochloride 5 selinexor 4 mogamulizumab 4 liposomal doxorubicin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07470996 2026-03-13

T-START-NR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡